Neuromuscular Disease in Primary Hyperparathyroidism
- BERNARD M. PATTEN, M.D.;
- JOHN P. BILEZIKIAN, M.D.;
- L. E. MALLETTE, M.D., Ph.D.;
- ALAN PRINCE, M.D.;
- W. KING ENGEL, M.D.; and
- G. D. AURBACH, M.D.
Abstract
Fourteen of 16 patients with primary hyperparathyroidism studied prospectively had weakness, easy fatiguability, and atrophy of muscles—particularly of the lower extremities. Electromyograms of these patients showed short-duration, low-amplitude motor unit potentials in some patients and abnormally high amplitude, long-duration polyphasic potentials in others. Motor nerve conduction velocities and distal sensory latencies were normal. The major finding on muscle biopsy was atrophy of both type I and type II muscle fibers, with type II fibers more extensively involved. Typical myopathic features were absent. A low concentration of phosphate in about half the patients was the only cerebrospinal-fluid abnormality noted. No patient had elevated serum glutamicoxalacetic transaminase, creatinine Phosphokinase, or aldolase values. All patients from whom a parathyroid adenoma was removed were significantly better within days to a few weeks of surgery. We conclude that many patients with hyperparathyroidism have treatable neuromuscular disease that is neuropathic in origin.
Article and Author Information
-
▸ From the Medical Neurology Branch, National Institute of Neurological Diseases and Stroke; and the Section on Mineral Metabolism, Metabolic Disease Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases; National Institutes of Health, Bethesda, Maryland.
-
▸ Requests for reprints should be addressed to Bernard M. Patten, M.D., Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, TX 77025.
-
- Received June 8, 1973.
- Accepted October 15, 1973.
RSS Feeds









